Anzeige
Mehr »
Sonntag, 05.07.2026 - Börsentäglich über 12.000 News
Milliardenkonkurrenten im Visier: Dieser KI-Wert gewinnt namhafte Großkunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9PC | ISIN: CNE100003FF7 | Ticker-Symbol: 8SJ
Frankfurt
03.07.26 | 15:25
2,080 Euro
+2,97 % +0,060
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI JUNSHI BIOSCIENCES CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI JUNSHI BIOSCIENCES CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
2,0802,12004.07.

Aktuelle News zur SHANGHAI JUNSHI BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoJUNSHI BIO Opens 11.11% Higher After Signing Licensing Agreement with Fosun Wanbang2
DoJunshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)568SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...
► Artikel lesen
MiJUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF THE LICENSE AGREEMENT WITH FOSUN WANBANG-
26.06.JUNSHI BIO (01877): SUPPLEMENTAL ANNOUNCEMENT CONNECTED TRANSACTION - ENTERING INTO OF THE JOINT VENTURE AGREEMENT-
26.06.JUNSHI BIO (01877): ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF THE BOARD COMMITTEES-
26.06.JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
26.06.JUNSHI BIO (01877): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING1
SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln
15.06.JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGE IN EQUITY OF THE SHAREHOLDERS ...1
05.06.JUNSHI BIO (01877): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 20261
05.06.JUNSHI BIO (01877): NOTICE OF THE 2025 ANNUAL GENERAL MEETING-
05.06.JUNSHI BIO (01877): 2025 AGM CIRCULAR-
05.06.JUNSHI BIO (01877): CONNECTED TRANSACTION - ENTERING INTO OF THE JOINT VENTURE AGREEMENT-
05.06.JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES2
05.06.JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CHANGE IN SHAREHOLDING STRUCTURE OF IMPLEMENTING ...1
05.06.JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS-
05.06.JUNSHI BIO (01877): RE-DESIGNATION OF DIRECTOR RETIREMENT UPON EXPIRY OF TERM AND PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION ...2
27.05.Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC692SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...
► Artikel lesen
27.05.Junshi Biosciences completes phase III lung cancer study2
26.05.JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - TORIPALIMAB IN COMBINATION WITH CHEMOTHERAPY AS PERIOPERATIVE TREATMENT FOR RESECTABLE STAGE II-III NSCLC ...-
21.05.JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION OF TORIPALIMAB FOR THE FIRST-LINE TREATMENT OF HER2 EXPRESSING ...5
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1